

## **CANQURA – TESTING THE DRUG FOR USE IN HUMAN**

### **Tests to see if QURA-100 kills AML in live animal**

Shareholders and colleagues – This is a very exciting phase of the realisation of our goal to see Canqura (formally DuecomplusA) utilised as a real treatment for AML. This phase, sees the tests through to preparation for live human testing.

The 5 steps we are about to undertake and have already started are listed here – explained in layman’s terms – with approximate time lines and costs.

As each step is achieved, we will advise you with a reminder where we are, but here is a brief summarised version:

**Step 1** – Is to produce a quantity of our patented product for specific use in these tests.

**Step 2** – We have to produce the publication and written materials for the set up and what we are undertaking.

**Step 3** – We begin testing doses and the tolerance of dose sizes in mice.

**Step 4** – Is to compile the risk assessment for human testing using what we have learned so far.

**Step 5** – By the end of this year and into next we are going to be testing the drug with AML infected live mice.

Once step 5 is completed and reported, we are then ready to launch into human testing phase. Steps 1 – 5 will show very clearly whether or not Canqura is really going to work in the fight to cure AML!

**Please share this with your friends!**

**With best regards**

**Jeremy Clark and the Canqura Team!**